ClinicalTrials.gg
CompletedNCT01253265Updated May 26, 2016Results posted

A Study in Rheumatoid Arthritis

A Phase 1 interventional study of LY2439821 and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 8 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.

Enrollment
29th of 35
32 · median 164
Started
2010
with 4 others
Phase 1
8 of 35
2 open now
Registered
13th of 35
by date

Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 29th largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 1, and was the 13th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses of LY2439821 in Japanese patients with rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory male or female patients between the ages of 20 and 75 years
  • Male patients: Agree to use a reliable method of during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing. Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding. Women of child bearing potential must agree to use a reliable method of birth control during the study.
  • Patients who are between the body weight of 40 and 105 kilogram (kg)
  • Patients who have an established diagnosis of Rheumatoid Arthritis (RA)
  • Patients who have C reactive protein (CRP) measurement greater than the or erythrocyte sedimentation rate of at least 28 millimeters per hour (mm/hr)
  • Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks
  • Patients who have given written approved by the Sponsor and the Institutional Review Board (IRB) governing the site
  • Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • Patients who use oral at average daily doses of >10 mg/day of prednisone or its equivalent or use of variable doses of oral corticosteroids within the last 4 weeks
  • Patients who have had a within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks
  • Patients who have a diagnosis of any systemic inflammatory condition other than RA
  • Patients who have evidence of active vasculitis or uveitis
  • Patients who have a diagnosis of Felty's syndrome
  • Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study
  • Patients who have had lymphoma, leukemia, or any within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease
  • Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection
  • Patients who have an evidence or suspicion of active tuberculosis (TB) by medical history, physical examination, and/or chest radiograph or documentation of TB by a positive purified protein derivative (PPD) test
  • Patients who have uncontrolled arterial hypertension characterized by a systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg
  • Patients who have an evidence of positive (HBV) surface antigen, positive hepatitis B surface antibody, positive hepatitis B core antibody, or hepatitis B DNA (HBV DNA); an evidence of (HIV), evidence of hepatitis B; or an evidence of
  • Patients who have clinical laboratory test results at entry that are outside the normal reference range, or results with unacceptable deviations that are considered by the investigator
  • Patients who have a serum creatinine >2.0 milligrams per deciliter (mg/dL)
  • Patients who have known hypogammaglobulinemia or a serum immunoglobulin (Ig) G (IgG), IgM, or IgA concentration less than the lower limit of normal
  • Patients who have an abnormality in the 12 lead (ECG).
  • Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days
  • Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer
  • Patients who previously completed or withdrawn from this study or any other study investigating LY2439821
  • Patients who have been treated with any biologic DMARD currently or previously for 5 half lives
  • Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)
  • Patients who have received non biologics DMARDs (other than MTX, sulfasalazine, bucillamine or hydroxychloroquine)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    30 mg LY2439821

    Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10

    Drug: LY2439821

  • Experimental
    80 mg LY2439821

    Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10

    Drug: LY2439821

  • Experimental
    180 mg LY2439821

    Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10

    Drug: LY2439821

  • Placebo comparator
    Placebo

    Placebo is administered subcutaneously in the same manner as active drug in each dose group

    Drug: Placebo

  • Experimental
    120 mg LY2439821

    Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week

    Drug: LY2439821

Interventions

  • Administered subcutaneously

  • DrugPlacebo

    Administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Effects

    Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.

    Time frame: Baseline up to 26 weeks

Secondary outcomes

  1. Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein

    C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.

    Time frame: Baseline, 16 weeks

  2. Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)

    Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).

    Time frame: Baseline, 16 weeks

  3. Change From Baseline to 26 Week Endpoint in Neutrophil Counts

    Time frame: Baseline, 26 weeks

  4. Change From Baseline to 26 Week Endpoint in Lymphocyte Counts

    Time frame: Baseline, 26 weeks

  5. Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)

    AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)

    Time frame: Week 10 pre-dose up to 2 weeks post-dose (Week 12)

  6. Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)

    Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)

    Time frame: Week 10 pre-dose up to 2 weeks post-dose (Week 12)

  7. Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)

    tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)

    Time frame: Week 10 pre-dose up to 2 weeks post-dose (Week 12)

07

Results

Posted May 26, 2016

Participant flow

Participant flow — Overall Study
Milestone30 Milligram (mg) LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Started66668
Completed56667
Not completed10001
Withdrew: Met predefined discontinuation criteria10000
Withdrew: Withdrawal by subject00001

Outcome measures

PrimaryNumber of Participants With Clinically Significant Effects

Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.

Time frame:
Baseline up to 26 weeks
Reported as:
Number · participants
Number of Participants With Clinically Significant Effects
participants30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Serious Adverse Events00000
Other Adverse Events45336
SecondaryPercentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein

C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.

Time frame:
Baseline, 16 weeks
Reported as:
Median · percentage change in C-Reactive Protein
Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein
percentage change in C-Reactive Protein30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein-88.75 (-98.6 to -66.7)-73.81 (-98.8 to 180.0)-17.04 (-48.4 to 150.0)-95.47 (-99.3 to 100.0)-8.07 (-82.8 to 186.2)
SecondaryPercentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)

Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).

Time frame:
Baseline, 16 weeks
Reported as:
Median · percentage change in ESR
Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)
percentage change in ESR30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)-44.50 (-80.0 to -16.7)-35.05 (-76.1 to 13.3)-3.75 (-37.9 to 100.0)-73.08 (-92.7 to -5.6)-12.62 (-54.5 to 137.5)
SecondaryChange From Baseline to 26 Week Endpoint in Neutrophil Counts
Time frame:
Baseline, 26 weeks
Reported as:
Median · 10^9 cells per liter (GI/L)
Change From Baseline to 26 Week Endpoint in Neutrophil Counts
10^9 cells per liter (GI/L)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Change From Baseline to 26 Week Endpoint in Neutrophil Counts0.681 (-5.77 to 5.84)-0.559 (-2.62 to 5.62)-0.170 (-0.87 to 2.72)-2.677 (-2.87 to -0.70)-0.641 (-2.94 to 2.29)
SecondaryChange From Baseline to 26 Week Endpoint in Lymphocyte Counts
Time frame:
Baseline, 26 weeks
Reported as:
Median · 10^9 cells per liter (GI/L)
Change From Baseline to 26 Week Endpoint in Lymphocyte Counts
10^9 cells per liter (GI/L)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Change From Baseline to 26 Week Endpoint in Lymphocyte Counts0.189 (-1.19 to 1.23)-0.011 (-0.54 to 1.25)-0.184 (-0.37 to 0.09)0.138 (-0.15 to 0.65)0.085 (-0.56 to 0.24)
SecondaryPharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)

AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)

Time frame:
Week 10 pre-dose up to 2 weeks post-dose (Week 12)
Reported as:
Geometric mean · micrograms•day per milliliter(μg•day/mL)
Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)
micrograms•day per milliliter(μg•day/mL)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821
Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)77.2 ± 26151 ± 44437 ± 42208 ± 48
SecondaryPharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)

Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)

Time frame:
Week 10 pre-dose up to 2 weeks post-dose (Week 12)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)
micrograms per milliliter (μg/mL)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821
Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)7.05 ± 2613.5 ± 4339.3 ± 4233.1 ± 56
SecondaryPharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)

tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)

Time frame:
Week 10 pre-dose up to 2 weeks post-dose (Week 12)
Reported as:
Median · days
Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)
days30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821
Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)1.96 (1.91 to 7.00)1.93 (1.89 to 3.97)1.95 (1.88 to 2.02)3.89 (1.93 to 3.99)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 mg LY2439821—0/6 (0%)4/6 (66.7%)
80 mg LY2439821—0/6 (0%)5/6 (83.3%)
180 mg LY2439821—0/6 (0%)3/6 (50%)
120 mg LY2439821—0/6 (0%)3/6 (50%)
Placebo—0/8 (0%)6/8 (75%)
Most frequent other events
Showing 10 of 41
Most frequent other events
Event30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821Placebo
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/62/60/60/63/8
NasopharyngitisInfections and infestations0/60/60/60/62/8
Menopausal symptomsReproductive system and breast disorders1/40/60/30/40/5
Eyelid oedemaEye disorders0/60/60/61/60/8
Ocular hyperaemiaEye disorders0/61/60/60/60/8
Dry mouthGastrointestinal disorders0/61/60/60/60/8
Mouth ulcerationGastrointestinal disorders0/60/60/61/60/8
NauseaGastrointestinal disorders1/60/60/60/60/8
Administration site reactionGeneral disorders0/61/60/61/60/8
Feeling abnormalGeneral disorders0/60/60/61/60/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Mean53.0 ± 15.456.8 ± 7.261.7 ± 11.352.5 ± 14.060.1 ± 7.757.0 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Female4634522
Male2032310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Japanese6666832
Region of Enrollment
Region of Enrollment(participants)30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Japan6666832
C-Reactive Protein (CRP)
C-Reactive Protein (CRP)(milligrams per liter (mg/L))30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Median7.950 (5.00 to 25.10)11.750 (2.00 to 50.10)3.500 (2.80 to 12.80)31.000 (9.30 to 95.20)5.650 (1.10 to 50.10)9.700 (1.10 to 95.20)
Erythrocyte Sedimentation Rate (ESR)
Erythrocyte Sedimentation Rate (ESR)(millimeters per hour (mm/h))30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Median28.0 (7 to 87)53.5 (23 to 107)26.0 (4 to 50)42.5 (22 to 81)25.5 (9 to 48)29.5 (4 to 107)
Neutrophils
Neutrophils(10^9 cells per liter (GI/L))30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Median6.763 (3.13 to 7.67)4.293 (2.59 to 11.12)3.857 (2.59 to 5.26)6.056 (4.63 to 7.56)6.757 (4.14 to 8.97)5.261 (2.59 to 11.12)
Lymphocytes
Lymphocytes(10^9 cells per liter (GI/L))30 mg LY243982180 mg LY2439821180 mg LY2439821120 mg LY2439821PlaceboTotal
Median0.993 (0.42 to 2.62)1.156 (0.69 to 2.19)1.187 (0.88 to 2.01)1.379 (0.67 to 2.45)1.295 (1.06 to 2.29)1.275 (0.42 to 2.62)

2 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 820-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 673-1462, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ibaragi, 316-0035, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagasaki, 857-1165, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Niigata, 940-2085, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 712-8044, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shimane, 699-0293, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 164-8541, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2010
First posted
Dec 3, 2010
Start
May 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
May 26, 2016
Last update
May 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01253265
Responsible party
Sponsor
First posted
Dec 3, 2010
Start date
May 2010
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
May 26, 2016
Last update
May 26, 2016

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion